ICLR

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced a multi-year collaboration with Anthropic to bring Claude's AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON's digital innovation and AI strategy, and builds on Orbis – ICON's secure, governed, agentic AI platform. Through this collaboration, ICON will work closely with Anthropic's Life Sciences research team to explore and apply cutting-edge technologies that can accelerate innovation a.

Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock?

DUBLIN--(BUSINESS WIRE)--ICON Schedules Second Quarter 2026 Earnings Conference Call.

Investors interested in stocks from the Medical Services sector have probably already heard of Avantor, Inc. (AVTR) and Icon PLC (ICLR). But which of these two stocks is more attractive to value investors?

Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating: ICON plc (NASDAQ: ICLR) shareholders should email fletcher@fmoorelaw.com What is the Investigation About ? On February 12, 2026, ICON issued a press release entitled "ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices.

ICLR is tapping CRO demand, AI workflows and wider trial access, but uneven revenue trends and margin resets keep its earnings recovery in focus.

ICON trades below its five-year median, but weaker 2026 guidance, control issues and leverage keep the stock in wait-and-see territory.

ICON's stronger bookings and backlog hint at improving demand, but margin pressure, earnings declines and control remediation keep 2026 cautious.

ICON plc delivered a modest 1Q26 beat, with EPS of $2.50 and revenue of $2.03B, but growth was subdued and margins compressed. ICLR reaffirmed FY26 guidance—revenue of $7.85–$8.15B and EPS of $10–$11—signaling management confidence in a back-half recovery. Profitability faced pressure as adjusted EBITDA fell over 20% and margins dropped to 15.6%, driven by business mix and integration costs.